Finanzen von Immix Biopharma Inc (IMMX)IMMXImmix Biopharma Inc

Evaluating the bottom line, Immix Biopharma, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -34.18%, provide a clear picture of how effectively IMMX converts its operational activities into shareholder value.

In the context of the broader market, IMMX competes directly with industry leaders such as SGMT and ACHV. With a market capitalization of $740.24M, it holds a leading position in the sector. When comparing efficiency, IMMX's gross margin of N/A stands against SGMT's N/A and ACHV's N/A. Such benchmarking helps identify whether Immix Biopharma, Inc. is trading at a premium or discount relative to its financial performance.

The company has shown significant growth over the past year with a 140.41% increase, but it continues to report negative net income, with losses increasing to -11,557,002 USD in Q2 2026.